Physician

Jusmin R Patel, M.D.

According to 2025 Medicare claims, Jusmin Patel, M.D. (NPI: 1518259647) practices nephrology in the Carson City, NV market, with the plurality of this provider's patient population coming from Carson City, NV. This provider's primary affiliated billing organization is ONEILL CLARK NARVARTE & VICKS A PROFESSIONAL CORPORATION (NPI: 1962501940; TIN: 201405833) and primary practice location at 89706-9998.

Patel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 665 traditional Medicare patients, billed 1,796 HCPCS/CPT codes, and received $158,704 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 924 prescription claims across 247 beneficiaries totaling $593,659 in drug costs, led by Jynarque (Tolvaptan). DME data shows 190 claims. Open Payments data shows 110 records totaling $39,881. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $118,441 to $158,704. In contrast, Part D prescription costs have moved sharply higher in recent years, from $6,572 to $593,659. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	360	2,820	$118,441
2017	708	8,006	$310,512
2018	883	4,655	$307,586
2019	888	3,898	$427,238
2020	669	3,090	$361,922
2021	627	3,911	$240,792
2022	565	6,074	$222,730
2023	527	1,445	$171,835
2024	665	1,796	$158,704

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	31	154	$6,572
2016	57	228	$13,033
2017	100	382	$108,345
2018	107	451	$133,965
2019	146	778	$173,877
2020	126	602	$285,818
2021	136	530	$88,412
2022	132	497	$134,861
2023	160	659	$202,438
2024	247	924	$593,659

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	25	$3,241
2019	N/R	N/R	N/R
2020	N/R	11	$211
2021	N/R	45	$1,271
2022	N/R	48	$966
2023	N/R	80	$1,394
2024	N/R	190	$3,659

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	79	85	$131
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	66	100	$91
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	147	386	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	369	544	$69
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	191	238	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jynarque	Tolvaptan	13	364	$256,608
Farxiga	Dapagliflozin Propanediol	112	7,000	$123,603
Jardiance	Empagliflozin	49	3,510	$66,253
Xphozah	Tenapanor Hcl	12	360	$34,948
Kerendia	Finerenone	27	1,560	$32,928

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	41	$1,097
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	70	$1,003
J7515	Cyclosporine, oral, 25 mg	N	N/R	14	$654
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	29	$527
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	36	$377

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	103	$18,705	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	7	$21,177	Hoffmann-La Roche Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jusmin R. Patel, M.D.?

Tedicare shows public-source Medicare data for Jusmin R. Patel, M.D. (NPI 1518259647), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jusmin R. Patel, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jusmin R. Patel, M.D.?

Jusmin R. Patel, M.D. is linked to ONEILL CLARK NARVARTE & VICKS A PROFESSIONAL CORPORATION (billing NPI 1962501940) in the available physician profile data.

Does Jusmin R. Patel, M.D. have Open Payments data?

Jusmin R. Patel, M.D. has 110 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.